Loading institutional data...
Loading institutional data...
No institutional (13F) filings cover this company, so the Overview and 13F tabs are thin. Everything drawn from its SEC filings is here.
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $41.88 today, the market must believe free cash flow compounds 9.8%/yr for a decade (off $423M normalized FCF).
The market's 9.8% is more optimistic than its 9-yr track record.
2-stage DCF · 0.22B shares · net debt $815M
mean 12.6% · volatility σ 38% · implied rate exceeded in 5/9 yrs
Central path = implied 9.8%/yr growth; shaded band = ±1σ (38%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
EOD close · as of 2026-09-14
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.09B 100.0% | $1.98B 100.0% | $1.97B 100.0% | $2.14B 100.0% | $2.25B 100.0% | $1.87B 100.0% | $1.53B 100.0% | $1.50B 100.0% | $1.42B 100.0% | $1.34B 100.0% |
| Cost of Revenue | $790.5M 37.8% | $1.01B 51.1% | $731.6M 37.2% | $757.0M 35.3% | $800.8M 35.6% | $637.6M 34.1% | $521.2M 34.1% | $500.9M 33.4% | $495.0M 34.9% | $493.3M 36.9% |
| Cost of Products | — | — | — | — | — | — | — | — | $495.0M 34.9% | $493.3M 36.9% |
| Gross Profit | $1.30B 62.2% | $967.4M 48.9% | $1.23B 62.8% | $1.38B 64.7% | $1.45B 64.4% | $1.23B 65.9% | $1.01B 65.9% | $1.00B 66.6% | $922.6M 65.1% | $844.7M 63.1% |
| Selling, General & Admin | $125.7M 6.0% | $113.4M 5.7% | $119.3M 6.1% | $129.7M 6.1% | $128.1M 5.7% | $111.7M 6.0% | $112.3M 7.4% | $104.6M 7.0% | $102.1M 7.2% | $376.3M 28.1% |
| Total Operating Expenses | $833.6M 39.9% | $869.6M 44.0% | $823.8M 41.9% | $853.1M 39.8% | $820.7M 36.5% | $846.3M 45.2% | $1.03B 67.6% | $734.4M 48.9% | $769.1M 54.3% | $745.8M 55.7% |
| Operating Income | $465.9M 22.3% | $97.7M 4.9% | $409.9M 20.9% | $531.5M 24.8% | $630.1M 28.0% | $386.4M 20.7% | -$26.1M -1.7% | $266.6M 17.8% | $153.4M 10.8% | $98.8M 7.4% |
| Interest Expense | $33.3M 1.6% | $43.8M 2.2% | $53.4M 2.7% | $58.4M 2.7% | $54.5M 2.4% | $71.3M 3.8% | $74.2M 4.9% | $67.3M 4.5% | $49.7M 3.5% | $39.0M 2.9% |
| Interest & Investment Income | $64.3M 3.1% | $68.0M 3.4% | $79.0M 4.0% | $32.8M 1.5% | $9.6M 0.4% | $10.0M 0.5% | $22.1M 1.4% | $20.9M 1.4% | $10.6M 0.8% | $6.8M 0.5% |
| Other Income (Expense), net | $24.4M 1.2% | $23.4M 1.2% | $19.9M 1.0% | -$18.9M -0.9% | -$4.3M -0.2% | $53.0M 2.8% | -$51.6M -3.4% | -$40.8M -2.7% | -$39.0M -2.8% | -$41.9M -3.1% |
| Pretax Income | $490.3M 23.5% | $121.1M 6.1% | $429.8M 21.9% | $512.6M 23.9% | $625.8M 27.8% | $439.5M 23.5% | -$77.8M -5.1% | $225.7M 15.0% | $114.4M 8.1% | $56.9M 4.3% |
| Income Tax Expense | $65.4M 3.1% | $37.6M 1.9% | $88.5M 4.5% | $89.4M 4.2% | $113.2M 5.0% | $80.3M 4.3% | -$36.3M -2.4% | $35.4M 2.4% | $74.0M 5.2% | -$23.4M -1.7% |
| Net Income | $424.9M 20.3% | $83.6M 4.2% | $341.3M 17.4% | $423.2M 19.8% | $512.6M 22.8% | $359.2M 19.2% | -$41.5M -2.7% | $190.4M 12.7% | $40.4M 2.8% | $80.4M 6.0% |
| Per Share | ||||||||||
| EPS (Basic) | $1.96 | $0.38 | $1.50 | $1.86 | $2.25 | $1.57 | $-0.18 | $0.84 | $0.18 | $0.34 |
| EPS (Diluted) | $1.94 | $0.37 | $1.48 | $1.84 | $2.21 | $1.53 | $-0.18 | $0.82 | $0.17 | $0.34 |
| Weighted Avg Shares (Basic) | 217.2M | 222.6M | 228.1M | 227.6M | 228.0M | 228.4M | 226.8M | 226.6M | 228.1M | 234.8M |
| Weighted Avg Shares (Diluted) | 218.9M | 224.7M | 230.6M | 230.1M | 232.0M | 234.2M | 226.8M | 233.5M | 233.0M | 239.0M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Insufficient balance-sheet detail (needs retained earnings, working capital, equity).
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 12% of free cash flow, leaving room to grow it and fund buybacks. Last year: $54M dividends + $280M buybacks = $334M returned on $453M FCF.
1 consecutive years of dividend increases.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Modest payoff on reinvested capital. Current ROIC on all capital: 8%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $839M covers the $0 due within a year 839005000.0× over. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-31 (20-F).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~2.0% on $1.7B of debt.
Cash of $839M fully covers short-term debt of $0.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.27T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $999.5B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $641.1B | 24.1× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $463.1B | 110.9× | 33.1× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.4B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $347.5B | 29.0× | 20.1× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $254.0B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $231.3B | 34.6× | 30.0× | 5.2× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $205.6B | 26.8× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $181.7B | 21.6× | 19.9× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $179.5B | 27.7× | 19.4× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.5B | 20.4× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $143.7B | 40.3× | 29.8× | 5.8× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $134.2B | 48.0× | 36.9× | 13.3× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $132.0B | 33.9× | 28.9× | 11.0× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $130.4B | 18.5× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| LGVN | $121.6B | — | — | 101442.6× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $121.4B | 68.7× | 12.2× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| MDT | $120.1B | 25.1× | 12.7× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| SYK | $107.7B | 33.6× | 18.5× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $106.2B | 23.7× | 16.7× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $95.6B | 15.0× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $93.6B | 16.8× | 15.8× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $83.0B | 19.1× | 19.9× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| QGEN | $9.1B | 21.6× | 15.0× | 4.3× | 5.7% | 62.2% | 20.3% | 11.2% | 7.8% | 2.5× | — |
Peers = companies sharing QGEN's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
EOD close · as of 2026-09-14
No material risks flagged.
Where each multiple sits in its own 14-yr range · 12th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 66.7× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 33.4 | 34.1 | 34.1 | 35.6 | 35.3 | 37.2 | 51.1 | 37.8 |
| Gross Profit | 66.6 | 65.9 | 65.9 | 64.4 | 64.7 | 62.8 | 48.9 | 62.2 |
| SG&A | 7.0 | 7.4 | 6.0 | 5.7 | 6.1 | 6.1 | 5.7 | 6.0 |
| Operating Income | 17.8 | -1.7 | 20.7 | 28.0 | 24.8 | 20.9 | 4.9 | 22.3 |
| Income Tax | 2.4 | -2.4 | 4.3 | 5.0 | 4.2 | 4.5 | 1.9 | 3.1 |
| Net Income | 12.7 | -2.7 | 19.2 | 22.8 | 19.8 | 17.4 | 4.2 | 20.3 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on QGEN: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.